Sotio


Clinical-stage biopharmaceutical company focused on targeted oncology therapies including next-generation antibody‑drug conjugates (ADCs), an IL‑15‑based immunocytokine, and autologous dendritic‑cell vaccines. Operates discovery and translational research, preclinical testing and GMP cell‑therapy manufacturing with research laboratories in Prague and offices in Boston, Basel and Amsterdam. Maintains a certified and audited network of cooperating apheresis centres to support autologous cell collection and clinical supply logistics. Pursues in‑licensing, partnerships and M&A to build its oncology pipeline.

Industries

Biotechnology
Health Care
Medical
Oncology
Therapeutics
Biotechnology Research

Nr. of Employees

medium (51-250)


Patents

IL-2/IL-15R beta gamma agonist dosing regimens for treating cancer or infectious diseases

US-12661387-B2

View Details

Humanized CLDN18.2 antibodies

US-12624100-B2

View Details

Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

US-10918704-B2

View Details

Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

US-10905751-B2

View Details

Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

US-10561717-B2

View Details

Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer

US-9895430-B2

View Details
View All Patents

Products

SOT109 (CDH17‑targeting ADC)

CDH17‑targeted antibody‑drug conjugate for colorectal and other gastrointestinal cancers; uses an exatecan‑class payload and optimized ADC design to enhance tumor selectivity and therapeutic index.

SOT106 (LRRC15‑targeting ADC)

ADC candidate targeting LRRC15 developed using in‑house antibody discovery integrated with external conjugation platform technologies.

Nanrilkefusp alfa (IL‑15 superagonist)

Subcutaneously administered IL‑15‑based immunocytokine fused to a receptor‑binding domain to selectively stimulate cytotoxic T cells and NK cells with an extended half‑life.

DCVAC autologous dendritic‑cell products

Personalized autologous dendritic‑cell immunotherapy products manufactured from patient leukapheresis material, pulsed with tumor antigens and cryopreserved for scheduled administration.

SOT201 (PD‑1‑targeting immunocytokine)

Next‑generation PD‑1‑targeting immunocytokine evaluated in Phase I for safety, tolerability and preliminary efficacy in advanced solid tumors.

DCVAC

Active cellular immunotherapy platform that uses the patient's own dendritic cells activated in vitro to reinforce the immune response to tumor cells in prostate, ovarian, and lung cancer.

View All Products

Services

GMP production, cryopreservation and release of autologous dendritic‑cell vaccine doses in certified facilities for clinical use.

Qualification, contracting, audit and coordination of certified apheresis centres for patient collection, plus logistics to transport starting material to manufacturing sites within defined timelines.

Design and operational execution of multicenter Phase I/II oncology trials with dose escalation and optimization cohorts.

Evaluation and integration of externally licensed assets and management of strategic collaborations to progress programs into clinical development.

Expertise Areas

  • Antibody‑drug conjugate development
  • Autologous cell therapy manufacturing and supply
  • Leukapheresis operations and apheresis centre qualification
  • Immunocytokine and cytokine immunotherapy development
  • Show More (5)

Key Technologies

  • Site‑specific antibody conjugation
  • Linker‑payload chemistry
  • Exatecan‑class cytotoxic payloads
  • Anthracycline payloads
  • Show More (7)

News & Updates

Preclinical data showed anti‑tumor activity in mouse xenograft models and favorable tolerability in exploratory mouse and non‑human primate studies; IND filing planned and first‑in‑human trial expected.

First participant dosed in the multicenter Phase 1/2 study evaluating a CDH17‑targeting ADC in colorectal cancer.

Regulatory Fast Track designation granted by the U.S. FDA to an investigational ADC targeting LRRC15 for soft tissue sarcoma, accelerating clinical development timelines.

Boards of Appeal of the EPO upheld European patent protection for a PD‑1‑targeting immunocytokine program currently in Phase I, strengthening intellectual property coverage.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.